Latest Ratios: P/E Ratio -5.8x · EV/EBITDA 18.3x · ROE -90.2%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.2B | $1.8B | $2.5B | $4.7B | $4.8B | $5.7B | $4.1B | $3.0B | $5.2B | $9.6B | $4.1B |
| Enterprise Value | $6.1B | $5.7B | $6.2B | $7.8B | $7.6B | $8.2B | $7.3B | $6.5B | $7.9B | $12.1B | $6.7B |
| P/E Ratio → | -5.76 | — | 29.65 | — | 8.39 | 9.32 | 18.78 | — | 5.18 | 12.80 | 552.25 |
| P/S Ratio | 0.38 | 0.31 | 0.44 | 0.77 | 0.71 | 0.89 | 0.83 | 0.54 | 0.78 | 1.55 | 0.75 |
| P/B Ratio | 8.84 | 7.07 | 4.19 | 6.36 | 4.38 | 5.23 | 5.06 | 4.29 | 5.05 | 11.05 | 38.96 |
| P/FCF | 43.46 | 34.80 | — | 25.25 | 10.82 | 10.54 | 7.64 | 17.64 | 8.03 | 41.93 | 15.83 |
| P/OCF | 8.40 | 6.72 | — | 8.45 | 6.42 | 6.96 | 5.11 | 4.59 | 4.52 | 14.96 | 6.82 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.98 | 1.07 | 1.28 | 1.12 | 1.29 | 1.47 | 1.18 | 1.19 | 1.96 | 1.24 |
| EV / EBITDA | 18.30 | 16.98 | 8.30 | 42.35 | 7.08 | 8.27 | 9.50 | 9.10 | 5.23 | 9.01 | 17.61 |
| EV / EBIT | — | — | 15.80 | — | 8.43 | 9.52 | 16.32 | 14.56 | 6.29 | 10.76 | 32.18 |
| EV / FCF | — | 111.53 | — | 41.90 | 17.02 | 15.27 | 13.51 | 38.52 | 12.34 | 53.14 | 26.15 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 15.5% | 15.5% | 19.9% | 21.5% | 23.7% | 21.8% | 21.5% | 19.2% | 29.7% | 28.4% | 20.6% |
| Operating Margin | -0.1% | -0.1% | 7.7% | -2.0% | 11.5% | 10.6% | 9.0% | 8.1% | 18.6% | 17.3% | 1.8% |
| Net Profit Margin | -6.6% | -6.6% | 1.5% | -3.9% | 8.5% | 9.6% | 4.4% | -0.9% | 15.0% | 12.1% | 0.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -90.2% | -90.2% | 12.8% | -25.8% | 52.8% | 64.1% | 29.0% | -6.1% | 105.6% | 154.0% | 6.0% |
| ROA | -5.2% | -5.2% | 1.1% | -3.0% | 7.6% | 8.3% | 3.1% | -0.7% | 13.6% | 11.2% | 0.1% |
| ROIC | -0.1% | -0.1% | 8.2% | -2.4% | 15.7% | 13.3% | 8.2% | 8.4% | 25.6% | 26.1% | 2.2% |
| ROCE | -0.1% | -0.1% | 7.7% | -2.1% | 13.7% | 11.9% | 7.9% | 7.9% | 21.8% | 21.6% | 2.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 18.27 | 18.27 | 7.20 | 5.82 | 3.50 | 3.68 | 5.25 | 6.43 | 3.89 | 4.75 | 34.08 |
| Debt / EBITDA | 13.69 | 13.69 | 5.85 | 23.36 | 3.60 | 4.02 | 5.57 | 6.25 | 2.62 | 3.06 | 9.33 |
| Net Debt / Equity | — | 15.59 | 6.02 | 4.19 | 2.51 | 2.34 | 3.89 | 5.08 | 2.72 | 2.95 | 25.40 |
| Net Debt / EBITDA | 11.68 | 11.68 | 4.90 | 16.83 | 2.58 | 2.56 | 4.13 | 4.93 | 1.83 | 1.90 | 6.95 |
| Debt / FCF | — | 76.73 | — | 16.65 | 6.20 | 4.72 | 5.87 | 20.88 | 4.32 | 11.21 | 10.32 |
| Interest Coverage | -0.03 | -0.03 | 1.48 | -0.53 | 5.55 | 4.65 | 2.13 | 2.15 | 6.46 | 5.24 | 0.95 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.78 | 1.78 | 1.68 | 1.54 | 1.70 | 1.80 | 1.83 | 1.80 | 1.93 | 2.12 | 1.44 |
| Quick Ratio | 0.85 | 0.85 | 0.86 | 1.00 | 0.96 | 1.21 | 1.17 | 1.10 | 1.26 | 1.55 | 1.01 |
| Cash Ratio | 0.40 | 0.40 | 0.40 | 0.48 | 0.58 | 0.78 | 0.77 | 0.61 | 0.70 | 0.94 | 0.51 |
| Asset Turnover | — | 0.79 | 0.77 | 0.74 | 0.89 | 0.84 | 0.70 | 0.76 | 0.90 | 0.85 | 0.89 |
| Inventory Turnover | 3.13 | 3.13 | 3.15 | 3.53 | 3.71 | 4.52 | 4.16 | 4.14 | 4.07 | 4.74 | 5.59 |
| Days Sales Outstanding | — | 42.67 | 48.61 | 36.63 | 33.45 | 41.42 | 37.54 | 44.52 | 47.34 | 54.25 | 54.55 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 3.5% | 4.4% | 5.8% | 3.2% | 3.2% | 2.9% | 4.0% | 5.5% | 2.9% | 0.2% | 0.5% |
| Payout Ratio | — | — | 172.1% | — | 26.6% | 27.0% | 74.9% | — | 14.9% | 2.9% | 314.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 3.4% | — | 11.9% | 10.7% | 5.3% | — | 19.3% | 7.8% | 0.2% |
| FCF Yield | 2.3% | 2.9% | — | 4.0% | 9.2% | 9.5% | 13.1% | 5.7% | 12.5% | 2.4% | 6.3% |
| Buyback Yield | 0.0% | 0.1% | 0.0% | 1.5% | 10.2% | 3.1% | 0.0% | 10.8% | 12.5% | 1.1% | 0.0% |
| Total Shareholder Yield | 3.6% | 4.5% | 5.8% | 4.6% | 13.4% | 6.0% | 4.0% | 16.3% | 15.4% | 1.3% | 0.5% |
| Shares Outstanding | — | $151M | $150M | $149M | $158M | $169M | $166M | $165M | $183M | $191M | $183M |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CC stock.
The Chemours Company's current P/E ratio is -5.8x. The historical average is 14.0x.
The Chemours Company's current EV/EBITDA is 18.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 13.0x.
The Chemours Company's return on equity (ROE) is -90.2%. The historical average is 25.3%.
Based on historical data, The Chemours Company is trading at a P/E of -5.8x. Compare with industry peers and growth rates for a complete picture.
The Chemours Company's current dividend yield is 3.51%.
The Chemours Company has 15.5% gross margin and -0.1% operating margin.
The Chemours Company's Debt/EBITDA ratio is 13.7x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
PFAS litigation and governance issues
Metrics are mathematically derived from official filings.
Margin Compression and Non-Recurring Charges
Gross margin fell from 20.9% in 2024Q1 to 18.0% in 2026Q2, while operating margin swung to -13.4%, according to reported financials, indicating pricing power erosion and one-time costs.
The steady decline in gross margin from 20.9% to 18.0% over ten quarters suggests input cost inflation or competitive pricing pressures are not being fully passed through. The operating margin collapse to -13.4% in 2026Q2, versus positive margins in prior quarters, appears driven by non-recurring items such as litigation accruals or restructuring, as CEO commentary points to adjusted EBITDA near guidance. Investors should monitor whether core operations can return to the 5-8% operating margin range seen in 2024, as the current negative margin is not sustainable.
Return on Capital Decaying Amid Losses
ROIC has turned negative at -4.3% in 2026Q2, down from +2.3% in 2024Q2, as per quarterly data, indicating that the company is destroying value on its invested capital.
The deterioration in ROIC from a stable 2% range in 2024 to negative territory in 2026 reflects both margin compression and an expanding capital base due to environmental liabilities. The negative ROE of -3.3% in 2026Q2, following a -93% plunge in 2025Q2, underscores the impact of cumulative losses on equity. This suggests the company is not compounding returns, and the capital employed in TiO2 and fluorochemicals is not generating adequate returns during the current cyclical trough.
Working Capital Efficiency Stretched
Cash conversion cycle lengthened to 90 days in 2026Q2 from 75 days in 2024Q1, as reported in financial statements, driven by rising DIO and stable DSO, indicating slower inventory turnover.
The CCC expansion from 75 to 90 days is primarily due to DIO increasing from 116 to 104 days (though it peaked at 122 in 2025Q4), while DPO has declined from 87 to 62 days, reducing supplier financing. This suggests the company is holding more inventory relative to sales, possibly due to weak demand, and is paying suppliers faster, which strains cash flow. Asset turnover remains low at 0.22, consistent with a capital-intensive business, but the working capital drag is a concern in a period of negative earnings.
Leverage Metrics Distorted by Negative Equity
Debt-to-equity spiked to 20.33 in 2026Q1 before equity turned negative, while interest coverage fell to -7.25 in 2026Q2, per balance sheet data, indicating severe debt service strain.
The reported D/E ratios are misleading because equity has eroded to -$49M in 2026Q2, making traditional leverage ratios meaningless. Interest coverage turned negative at -7.25 in 2026Q2, down from 2.05 in 2024Q2, implying that operating income is insufficient to cover interest expenses. This suggests heightened refinancing risk and potential covenant breaches, especially if the company needs to refinance its $4.1B debt during a period of weak profitability.
Liquidity Ratios Mask Thin Cash Buffer
Current ratio improved to 1.66 in 2026Q2, but quick ratio of 0.88 and cash of $671M versus $4.1B debt, as per balance sheet, indicate a tight liquidity position.
The current ratio above 1.5 appears comfortable, but the quick ratio below 1.0 reveals reliance on inventory, which may be hard to liquidate in a downturn. Cash of $671M covers only 16% of total debt, and with negative operating income, the company may need to draw on credit lines or sell assets to meet obligations. The liquidity position appears adequate for the near term but would be vulnerable under a prolonged downturn or if environmental liabilities require immediate cash outflows.
Misapplied EV/EBITDA in Cyclical Downturn
EV/EBITDA of 18.53 appears elevated, but forward EV/EBITDA of 9.08 suggests the market expects recovery, as per valuation data, yet this multiple is distorted by depressed EBITDA.
The most commonly misapplied ratio for Chemours is EV/EBITDA, because current EBITDA is depressed by cyclical and one-time factors, making the trailing multiple misleadingly high. Investors should instead use a mid-cycle EBITDA estimate or EV/EBIT to normalize for the TiO2 cycle and non-recurring charges. The forward multiple of 9.08 implies a sharp earnings recovery, but this hinges on the resolution of PFAS liabilities and a TiO2 upturn, which are uncertain. A more appropriate metric is EV/Invested Capital or EV/ton of TiO2 capacity to assess the franchise value independent of cyclical earnings.